Allergy

Peanuts
#Allergy #Collaborative Drug Discovery (CDD) #Immunotherapy

Advancing oral immunotherapy for food allergies

Professor Mimi Tang discusses multi-year follow up from the PPOIT-003 Phase IIb programme and how these data help clarify distinct post-treatment clinical states, including remission and desensitisation, and their implications for durability, adherence, and real-world patient experience once structured therapy is complete.  Recent multi-year data from the PPOIT-003 and PPOIT-003LT… Read More

#Exclusive Content

IgE antibody
#Allergy #Mergers and acquisitions #Novartis

Novartis acquires allergy experts Excellergy for $2 billion

Novartis has agreed to acquire Excellergy, a biotechnology company developing a novel class of allergy therapeutics, in a transaction with a total potential value of up to $2 billion in upfront and milestone payments.   Excellergy’s Exl-111 is a trifunctional effector cell response inhibitor (ECRI) designed to disarm… Read More

#Business & Investment #News

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

#Allergy #Immune cells #Therapeutic targets

Allergies could be treated by therapeutic target, study finds 

Researchers have uncovered a new target which could help treat severe allergic diseases.  In a study published in The Journal of Allergy and Clinical Immunology, a team led by Associate Professor Tomoaki Ando and Professor Jiro Kitaura at Juntendo University Graduate School of Medicine identified Fab (fragment antigen-binding) antibody… Read More

#News

GSK offices
#Allergy #GSK #Mergers and acquisitions #Monoclonal antibodies #RAPT Therapeutics

GSK expands food allergy pipeline with RAPT purchase

GSK has entered a definitive agreement to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for inflammatory and immunologic diseases.   The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in Phase IIb clinical development for prophylactic protection against food allergens. … Read More

#Business & Investment #News

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #DDW Highlights podcast #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

DDW Highlights: 16 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative treatments showed potential to treat neurodegenerative diseases, allergies and arthritis. Elsewhere,… Read More

#Podcasts

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

This week in Drug Discovery (8 – 12 December) 

News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative treatments have been developed for neurodegenerative diseases, allergies and arthritis. Elsewhere, China is becoming the dominant force in the biotech sector.  The top stories:   … Read More

#News

Peanut butter
#Allergen immunotherapy #Allergy #Clinical trial

Immunotherapy could treat nut allergies, results show 

A new immunotherapy could treat patients with nut allergies, preliminary results show.  VLP Peanut, an immunotherapy developed by biotechnology company Allergy Therapeutics, reached its primary endpoint in the Phase I/IIa PROTECT trial, with results showing the immunotherapy was safe and well-tolerated. The treatment was evaluated in 48 patients, with a… Read More

#News

Peanuts
#Allergy #Biopharmaceutical

Prota awarded for research on peanut oral immunotherapy

Biopharmaceutical company Prota Therapeutics has announced its research, in partnership with Murdoch Children’s Research Institute (MCRI), has been awarded a prize at the European Academy of Allergy and Clinical Immunology (EAACI) for outstanding oral abstract presentation.  The presentation reported three-year post-treatment findings from the Phase IIb PPOIT-003… Read More

#News

Doxepin antihistamine
#Allergy #Antihistamines #Tokyo University of Science

Discovery paves the way to next-generation antihistamines

Researchers in Japan have revealed why geometric variants of doxepin have markedly different efficacies, paving the way to next-generation antihistamines with fewer side effects. Doxepin is an antihistaminic, antidepressant, and sleeping aid that has two geometric isomers ­– molecules with equal chemical formulas but different 3D… Read More

#Editor's Choice #News

#Allergy #CHMP #FDA #Melanoma #Regulatory #Schizophrenia #Scleroderma

This week in drug discovery (26 Feb – 1 March) 

News round-up for 26 Feb – 1 March by DDW Digital Content Editor Diana Spencer. The news highlights this week all focus on regulatory decisions, both positive and negative. The first therapy was approved for allergic reactions to food, a drug for scleroderma secured Fast Track Designation, and… Read More

#News

Peanut butter
#Allergy #FDA #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases #Phase III trial

FDA approves first medication to reduce allergic reactions

The US Food and Drug Administration (FDA) has approved monoclonal antibody Xolair (omalizumab) for immunoglobulin E-mediated food allergy in some adults and children one year or older for the reduction of allergic reactions (Type I). The FDA said that Xolair is intended for repeated use to… Read More

#News #Regulatory

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

New DDW Highlights episode live now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have heard about a number of studies that demonstrate an inventive… Read More

#News

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

This week in drug discovery (26-30 June)  

News round-up for 26-30 June by DDW Digital Content Editor Diana Spencer. This week we have heard about a number of studies that demonstrate an inventive solution to an old problem, either through the use of an original approach or new, advanced technology. Whether… Read More

#News

Peanuts
#Allergy #Antibodies #Antibody #IgGenix #Monoclonal antibodies

Could a monoclonal antibody treat peanut allergy?

IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany. The data shows that nearly all peanut-specific IgE antibodies… Read More

#News